Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effectiveness and safety of rabeprazole sodium, an
inhibitor of gastric acid secretion of the protein pump inhibitor (PPI) class, compared with
placebo in the treatment of gastrointestinal esophageal reflux disease (GERD) in infants 1 to
11 months of age.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.